netarsudil: Clinical Trials

8 trials of netarsudil, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated, 1 unknown. 8 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Completed 6, Terminated 1, Unknown 1
Phase 33Completed 1, Terminated 1, Unknown 1

Follow netarsudil: new trials by email Literature Review of netarsudil trials Research Report on netarsudil

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma
Phase 2 / Phase 3CompletedUniversity Hospital Dubrava502025-05-122026-09-09
Next Generation Rocklatan
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension
Phase 2CompletedAlcon Research6462024-09-042026-11-09
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Phase 2 / Phase 3UnknownWills Eye802023-02-062024-07-30
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
Netarsudil, Placebo - Fuchs' Endothelial Dystrophy
Phase 2 / Phase 3TerminatedPrice Vision Group192019-07-222023-02-06
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle - Ocular Hypertension, Open Angle Glaucoma
Phase 2CompletedAerie Pharmaceuticals122016-07-012018-04-17
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02% - Open Angle Glaucoma, Ocular Hypertension
Phase 2CompletedAerie Pharmaceuticals2982014-01-012019-06-04
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005% - Ocular Hypertension, Open Angle Glaucoma
Phase 2CompletedAerie Pharmaceuticals2242012-11-012018-04-17
Study of AR-13324 in Patients With Elevated Intraocular Pressure
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04% - Ocular Hypertension, Open Angle Glaucoma
Phase 2CompletedAerie Pharmaceuticals852012-03-012018-04-18

Conditions studied

Glaucoma, Open-Angle (5)  ·  Ocular Hypertension (5)  ·  Glaucoma (3)  ·  Corneal Edema (1)  ·  Fuchs' Endothelial Dystrophy (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Retinal Detachment (1)  ·  Vitreoretinopathy, Proliferative (1)

Sponsors

Aerie Pharmaceuticals (4)  ·  Alcon Research (1)  ·  Price Vision Group (1)  ·  University Hospital Dubrava (1)  ·  Wills Eye (1)

Countries

United States (7)  ·  Croatia (1)

Top investigators

Theresa Heah, MD (3)  ·  Francis W Price, Jr, MD (1)  ·  Jason Hsu, MD (1)  ·  Josip Pavan, MD, PhD (1)  ·  Nancy Ramirez, M.S. (1)

Results publications

PMID 26209587, PMID 33244711, PMID 42568743